Concepedia

A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non–Small-Cell Lung Cancer

D. Ross Camidge, Eamon M. Berge, Robert C. Doebele, Marc Ballas, Thierry Jahan, Missak Haigentz, David Hoffman, James Spicer, Howard West, Pablo Lee,

Journal of Thoracic Oncology · 2014 · 51 citations · 16 references

DOIFull text

Open access

References

16

Regression Models and Life-Tables

D. R. Cox · Journal of the Royal Statistical Society Series B (Statistical Methodology) · 1972 · 38.8K citations · Full text

, , +14

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Tony Mok, Yi‐Long Wu, Sumitra Thongprasert et al. · New England Journal of Medicine · 2009 · 8.2K citations · Full text

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

Alan Sandler, Robert J. Gray, Michael C. Perry et al. · New England Journal of Medicine · 2006 · 5.8K citations · Full text

A Direct Approach to False Discovery Rates

John D. Storey · Journal of the Royal Statistical Society Series B (Statistical Methodology) · 2002 · 5.7K citations · Full text

, , +16

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Tetsuya Mitsudomi, Satoshi Morita, Yasushi Yatabe et al. · The Lancet Oncology · 2009 · 4.1K citations

, , +10